Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (208)

« Back to Publications

Kidney function and mortality in Mexico: prospective study of 130 000 adults

Aguilar Ramirez D. et al, (2026), Kidney Medicine

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Neuen BL. et al, (2026), JAMA, 335, 233 - 244

Effects Of Empagliflozin On Kidney And Cardiac Magnetic Resonance Imaging Measures In Patients With Chronic Kidney Disease: An EMPA-KIDNEY Mechanistic Substudy

ZHU D. et al, (2025), American Journal of Kidney Diseases

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Turner M. et al, (2025), Hypertension (Dallas, Tex. : 1979)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

HORBY P. et al, (2025), The Lancet Infectious Diseases

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

HORBY PW. et al, (2025), The Lancet Infectious Diseases

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

HAYNES R. et al, (2025), EClinicalMedicine

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

Horby P. et al, (2025)

Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19

Horby P. et al, (2025)

The Prevention and Management of Chronic Kidney Disease among Patients with Metabolic Syndrome

ZHU D. et al, (2024), Kidney International

Blood Pressure, eGFR, and Kidney Mortality in Mexico: A Prospective Study of 150,000 Adults

Zhu D., (2024)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

ZHU D. et al, (2024), NDT International

ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL

Judge P. et al, (2024), Nephrology Dialysis Transplantation

Load More

1
2
3
4
5
6
7
...
»